Table 1

Demographics and clinical features of 22 patients with MOG-IgG

Female-to-male ratio14:8
Median age at symptom onset (years, range)30 (4–50)
AQP4-IgG positivity1 (4.5%)
Median follow-up duration (months, range)63 (7–200)
Clinical course
 Monophasic5 (22.7%)
 Multiphasic17 (77.3%)
 Median EDSS at last follow-up (range)2.0 (0.0–7.0)
 Median number of attacks (range)3 (1–16)
Diagnosis at last follow-up
 Neuromyelitis optica spectrum disorder10 (45.5%)
 Multiple sclerosis1 (4.5%)
 Idiopathic AQP4-IgG-negative optic neuritis4 (18%)
 Idiopathic AQP4-IgG-negative myelitis4 (18%)
 Other demyelinating syndrome3 (14%)
Clinical phenotype at the onset
 O8 (36%)
 M6 (27%)
 B5 (23%)
 Multifocal involvement3 (14%)
 O+M2/3 (67%)
 O+B1/3 (33%)
  • APQ4-IgG, aquaporin-4 immunoglobulin G; B, brain; EDSS, Expanded Disability Status Scale; M, myelitis; MOG-IgG, myelin oligodendrocyte protein immunoglobulin G; O, optic neuritis.